AstraZeneca PLC (LON:AZN) has received the US regulatory green light for a slow-release version of its type-2 diabetes treatment.
Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control.
America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials.